Jul. 24 at 7:18 PM
Citizens y'day reiterated
$GHRS Market Outperform-
$39 and said, "Focus remains on ongoing FDA engagement with strong Phase 2b and OLE data reinforcing the blockbuster potential of GH001"
$ATAI $JNJ $CMPS CYBN
$MNMD
Citizens added, "We reiterate our Market Outperform rating and
$39 risk-adjusted, DCF-derived price target on GH Research.
This morning, GH Research announced that it has received feedback from the FDA on the recent submission to address the clinical hold for GH001. Only one topic, the relevance respiratory tract histology findings in rats, remains open with the FDA and all other items for the hold have been resolved.
We remain comfortable that the rat findings are species specific.
Also today, the company announced final results from the open-label extension portion of the Phase 2b trial in treatment-resistant depression, with a remission rate consistent with interim results disclosed in February."
